Drug Trial Radar · NCT00680134
Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis
Last checked: Nov 20, 2026Latest source record: Feb 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jun 30, 2006
Primary completion
Aug 31, 2007
Study completion Aug 31, 2007
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690 solutions in the treatment of distal, subungual onychomycosis of the great toenail.
Conditions
- Onychomycosis
Interventions
AN2690Drug
AN2690 1% Solution, once daily for 180 days
AN2690Drug
AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete or partial clinical evidence of great toenail clearance or at least 2 mm of fungal clear linear great toenail growth plus a negative fungal culture from the treatment targeted toenail at the End-of-treatment (Day 180)Time frame: Day 180
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, San Francisco
San Francisco, California
Academic Dermatology Associates
Albuquerque, New Mexico
Columbia University Medical Center
New York, New York
DermResearch, Inc.
Austin, Texas
J&S Studies
Bryan, Texas
Endeavor Clinical Trials, PA & San Antonio Podiatry Associates, PC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.